JP2016540739A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016540739A5 JP2016540739A5 JP2016527328A JP2016527328A JP2016540739A5 JP 2016540739 A5 JP2016540739 A5 JP 2016540739A5 JP 2016527328 A JP2016527328 A JP 2016527328A JP 2016527328 A JP2016527328 A JP 2016527328A JP 2016540739 A5 JP2016540739 A5 JP 2016540739A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- peptide
- isolated peptide
- isolated
- arginine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 36
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 239000003814 drug Substances 0.000 claims 11
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 10
- 102000040430 polynucleotide Human genes 0.000 claims 9
- 108091033319 polynucleotide Proteins 0.000 claims 9
- 239000002157 polynucleotide Substances 0.000 claims 9
- 208000028389 Nerve injury Diseases 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 230000008764 nerve damage Effects 0.000 claims 6
- 230000000324 neuroprotective effect Effects 0.000 claims 5
- 108010011110 polyarginine Proteins 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 125000002038 D-arginyl group Chemical group N[C@@H](C(=O)*)CCCNC(=N)N 0.000 claims 3
- 102000007327 Protamines Human genes 0.000 claims 3
- 108010007568 Protamines Proteins 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229940048914 protamine Drugs 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
- 102000004961 Furin Human genes 0.000 claims 1
- 108090001126 Furin Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 235000009697 arginine Nutrition 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 230000009460 calcium influx Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000012202 endocytosis Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000001146 hypoxic effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000006240 membrane receptors Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000003470 mitochondria Anatomy 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 230000004898 mitochondrial function Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 230000016273 neuron death Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000009984 peri-natal effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 229950008679 protamine sulfate Drugs 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013904197A AU2013904197A0 (en) | 2013-10-30 | Neuroprotective peptides | |
| AU2013904197 | 2013-10-30 | ||
| AU2014902319A AU2014902319A0 (en) | 2014-06-17 | Neuroprotective peptides | |
| AU2014902319 | 2014-06-17 | ||
| PCT/AU2014/050326 WO2015061856A1 (en) | 2013-10-30 | 2014-10-30 | Neuroprotective peptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016540739A JP2016540739A (ja) | 2016-12-28 |
| JP2016540739A5 true JP2016540739A5 (enExample) | 2017-10-19 |
| JP6495270B2 JP6495270B2 (ja) | 2019-04-03 |
Family
ID=53003020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016527328A Active JP6495270B2 (ja) | 2013-10-30 | 2014-10-30 | 神経保護ペプチドを含有する医薬組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20160250285A1 (enExample) |
| EP (1) | EP3063168B1 (enExample) |
| JP (1) | JP6495270B2 (enExample) |
| CN (1) | CN106170491B (enExample) |
| DK (1) | DK3063168T3 (enExample) |
| ES (1) | ES2724932T3 (enExample) |
| WO (1) | WO2015061856A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9303063B2 (en) * | 2011-03-18 | 2016-04-05 | Duke University | Peptide compounds for suppressing inflammation |
| WO2014202834A1 (en) * | 2013-06-18 | 2014-12-24 | University Of Helsinki | Protamine in treatment of neuronal injuries |
| CN106170491B (zh) | 2013-10-30 | 2020-07-24 | 阿尔杰妮卡治疗学有限公司 | 神经保护肽 |
| ES2896224T3 (es) * | 2016-06-23 | 2022-02-24 | Japan Science & Tech Agency | Composición farmacéutica que comprende arginina para su uso en el tratamiento de la enfermedad de PolyQ |
| US10774122B2 (en) * | 2017-03-21 | 2020-09-15 | The Regents Of The University Of Michigan | ERG targeted therapy |
| AU2018247561A1 (en) * | 2017-04-02 | 2020-11-26 | Interk Peptide Therapeutics Limited | Compositions and methods for prophylaxis or treatment of pain |
| JP2022505101A (ja) * | 2018-10-18 | 2022-01-14 | ファンダメンタル ファーマ ゲーエムベーハー | Ｎｍｄａ受容体媒介毒性を調節するための新規の方法 |
| JP2021116244A (ja) * | 2020-01-23 | 2021-08-10 | 有機合成薬品工業株式会社 | 高純度プロタミン硫酸塩 |
| CN115385987B (zh) * | 2021-05-19 | 2024-08-02 | 中山大学 | 一种抗鱼类神经坏死病毒的穿膜肽及其应用 |
| JP2023022363A (ja) * | 2021-08-03 | 2023-02-15 | 国立大学法人北海道大学 | 細胞保護用剤 |
| CN114533874B (zh) * | 2022-01-27 | 2023-12-29 | 北京和舆医药科技有限公司 | Psd-95 gk结构域作为神经保护靶点的用途 |
| WO2026099761A1 (en) | 2024-11-06 | 2026-05-15 | Salem Yahya Ahmed | Peptides |
| CN119563880B (zh) * | 2025-01-24 | 2025-07-15 | 浙江工业大学 | 一种多肽负载沙棘果油微囊粉及其制备方法和应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4684624A (en) | 1983-12-22 | 1987-08-04 | Yoshio Hosobuchi | Method of treating cerebral ischemia |
| US5559095A (en) | 1989-11-22 | 1996-09-24 | Neurex Corporation | Delayed treatment method of reducing ischemia-related neuronal damage |
| WO1998041223A1 (en) | 1997-03-20 | 1998-09-24 | The Regents Of The University Of California | N-methyl-d-aspartate receptor channel blockers and method for identifying such |
| US6605115B1 (en) * | 1999-06-05 | 2003-08-12 | Board Of Trustees Of The Leland Stanford Junior University | Method and composition for inhibiting cardiovascular cell proliferation |
| DE60230071D1 (de) | 2002-06-14 | 2009-01-08 | Monier Tadros | Methode für die herstellung von protamin |
| GB0223193D0 (en) * | 2002-10-07 | 2002-11-13 | Ludwig Inst Cancer Res | Polypeptide |
| JP2007526316A (ja) | 2004-03-01 | 2007-09-13 | ルーメン セラピューティックス リミテッド ライアビリティ カンパニー | 疾患を処置するための組成物および方法 |
| EP1957093B1 (en) | 2005-08-29 | 2017-04-12 | SHASHOUA, Victor E. | Neuroprotective and neurorestorative methods and compositions |
| PL1969003T3 (pl) | 2005-12-14 | 2011-05-31 | Herantis Pharma Plc | Zastosowanie białka czynnika neurotroficznego |
| US20070269892A1 (en) * | 2006-05-18 | 2007-11-22 | Nastech Pharmaceutical Company Inc. | FORMULATIONS FOR INTRACELLULAR DELIVERY dsRNA |
| WO2008054544A2 (en) * | 2006-05-22 | 2008-05-08 | Immune Disease Institute, Inc. | Method for delivery across the blood brain barrier |
| EP1884521A1 (en) | 2006-07-31 | 2008-02-06 | Xigen S.A. | Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins |
| GB0702022D0 (en) * | 2007-02-02 | 2007-03-14 | Novabiotics Ltd | Peptides and their use |
| GB0702020D0 (en) * | 2007-02-02 | 2007-03-14 | Novabiotics Ltd | Peptides and their use |
| WO2008133929A2 (en) * | 2007-04-24 | 2008-11-06 | Yale University | Cell permeable miniature proteins |
| KR20090034239A (ko) * | 2007-10-02 | 2009-04-07 | 재단법인서울대학교산학협력재단 | 골형성 촉진용 세포투과성 융합 단백질 및 그 용도 |
| FI20080326A0 (fi) | 2008-04-30 | 2008-04-30 | Licentia Oy | Neurotroofinen tekijä MANF ja sen käytöt |
| CA2990678C (en) | 2009-11-06 | 2021-08-31 | The J. David Gladstone Institutes | Methods and compositions for modulating tau levels |
| NO2504357T3 (enExample) | 2009-11-23 | 2017-12-30 | ||
| US20120301446A1 (en) | 2010-02-04 | 2012-11-29 | Vivoscript, Inc. | Compositions and methods for re-programming cells without genetic modification for treatment of neurological disorders |
| WO2012050673A1 (en) * | 2010-10-14 | 2012-04-19 | Wisconsin Alumni Research Foundation | Methods for the treatment of x-linked hypophosphatemia and related disorders |
| WO2013076666A1 (en) * | 2011-11-23 | 2013-05-30 | Newsouth Innovations Pty Limited | Antimicrobial peptides and uses thereof |
| CA2857287A1 (en) | 2011-11-29 | 2013-06-06 | Mayo Foundation For Medical Education And Research | Peptide-mediated delivery of active agents across the blood-brain barrier |
| EP2872160A4 (en) * | 2012-04-17 | 2015-11-25 | Univ Brown | NERVO-PROTECTING COMPOSITION AND USE METHOD |
| WO2013163423A1 (en) * | 2012-04-25 | 2013-10-31 | Musc Foundation For Research Development | Compositions and methods for wound healing and tissue repair |
| EP2986115A4 (en) | 2013-02-06 | 2017-03-01 | Academia Sinica | Antimicrobial peptides derived from hepatitis b virus core protein arginine-rich domain |
| WO2014202834A1 (en) * | 2013-06-18 | 2014-12-24 | University Of Helsinki | Protamine in treatment of neuronal injuries |
| CN106170491B (zh) | 2013-10-30 | 2020-07-24 | 阿尔杰妮卡治疗学有限公司 | 神经保护肽 |
-
2014
- 2014-10-30 CN CN201480071971.3A patent/CN106170491B/zh active Active
- 2014-10-30 EP EP14858082.2A patent/EP3063168B1/en active Active
- 2014-10-30 US US14/392,392 patent/US20160250285A1/en not_active Abandoned
- 2014-10-30 DK DK14858082.2T patent/DK3063168T3/en active
- 2014-10-30 ES ES14858082T patent/ES2724932T3/es active Active
- 2014-10-30 WO PCT/AU2014/050326 patent/WO2015061856A1/en not_active Ceased
- 2014-10-30 JP JP2016527328A patent/JP6495270B2/ja active Active
-
2018
- 2018-07-20 US US16/041,483 patent/US11229678B2/en active Active
-
2021
- 2021-12-20 US US17/556,730 patent/US12303550B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY171146A (en) | Compositions of glp-1 peptides and preparation thereof | |
| JP2013520405A5 (enExample) | ||
| JP2012176978A5 (enExample) | ||
| NZ704011A (en) | Abuse deterrent pharmaceutical compositions for controlled release | |
| WO2012142320A3 (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
| JP2012501973A5 (enExample) | ||
| WO2017009842A3 (en) | Compositions and methods for treating cancer | |
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| EP4349359A3 (en) | Peptide exhibiting wrinkle-improving activity and uses thereof | |
| HRP20210577T1 (hr) | Sastavi i načini liječenja i sprječavanje upale | |
| HK1204988A1 (en) | Methods and compositions for preventing or treating ophthalmic conditions | |
| JP2019513752A5 (enExample) | ||
| WO2013096868A3 (en) | Saposin-a derived peptides and uses thereof | |
| PH12020500338A1 (en) | Acylated oxyntomodulin peptide analog | |
| JP2016540825A5 (enExample) | ||
| EA201290856A1 (ru) | Стабилизированная фармацевтическая композиция | |
| JP2016515123A5 (enExample) | ||
| EP3026057A3 (en) | Compositions for prevention and treatment of neurodegenerative diseases | |
| JP2013542196A5 (enExample) | ||
| WO2014039074A3 (en) | Therapeutic compositions and related methods | |
| BR112015022212A2 (pt) | sais estáveis de pentadecapeptídeo, processo para a preparação dos mesmos, uso dos mesmos na fabricação de preparações farmacêuticas e uso dos mesmos em terapia | |
| RU2017126212A (ru) | Композиция | |
| WO2011121607A3 (en) | Rasagiline and its pharmaceutically acceptable salts | |
| JP2010533660A5 (enExample) | ||
| WO2012002762A3 (ko) | 알러지성 질환의 치료 및 예방을 위한 펩타이드 |